An observational study in Hepatocellular Carcinoma (HCC), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Shanghai Zhongshan Hospital · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital — 27 open to participants now, 31 under way, 3 of them phase 3. Carcinoma, Hepatocellular · Shanghai Zhongshan Hospital.
Among the 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 9 that started in 2026, is one of 21 observational ones, reaches primary completion later than 25 of the 30 other live ones, and was the 56th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →27 of the 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–90
Shanghai Zhongshan Hospital · Sites in China
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 25 · Phase 3 9
First in 2014; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 44 across the 42 interventional studies, 300 across the 21 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
4 of the studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786792Shanghai Zhongshan HospitalBiomarker and Mechanism Study of Systemic Therapy in Unresectable HCC | 2027-01-01 |
| NCT07919717Shanghai Zhongshan HospitalNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | 2027-05-12 |
| NCT07781176Shanghai Zhongshan HospitalDifferent Acupoint Stimulation for Postoperative Gastrointestinal Dysfunction in Primary Liver Cancer Patients | 2027-07-31 |
| NCT07714317Shanghai Zhongshan HospitalPhase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 63 studies in Carcinoma, Hepatocellular by Shanghai Zhongshan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center prospective observational cohort study aims to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. Residual peripheral blood samples obtained during routine clinical testing will be analyzed without additional blood draws. The study hypothesizes that baseline and longitudinal peripheral blood biomarkers are associated with treatment response and can be used to identify patients more likely to benefit from T+A therapy. Treatment response will be evaluated based on the best overall response (BOR) during treatment. The primary efficacy assessment will be performed according to RECIST 1.1, while modified RECIST (mRECIST) will be used as a supportive assessment. Predictive models based on peripheral blood biomarkers will be developed using RECIST 1.1-defined treatment response as the primary analysis, with mRECIST used for supportive and sensitivity analyses.
This is a single-center prospective observational cohort study designed to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. T+A therapy has become a standard first-line treatment for advanced HCC; however, the objective response rate remains limited, and reliable non-invasive biomarkers for predicting treatment response are lacking. Consequently, accurate patient stratification and individualized prediction of treatment benefit remain challenging in clinical practice. We hypothesize that peripheral blood-based biomarkers, including serum-derived indicators such as secreted proteins, metabolites, and extracellular vesicle-related components, as well as peripheral blood cell-related markers, are associated with treatment response to T+A therapy and may help identify patients more likely to benefit from treatment. These biomarkers will be analyzed using approaches including proteomic and metabolomic analyses, extracellular vesicle-related assays, enzyme-linked immunosorbent assays (ELISAs), and peripheral blood cell-related analyses. Eligible patients scheduled to receive first-line T+A therapy will be consecutively enrolled at Zhongshan Hospital, Fudan University. When available, residual peripheral blood samples obtained during routine clinical testing will be collected at baseline, at routine treatment visits approximately every 3 weeks, and at the time of first documented disease progression. All participants will provide written informed consent for the use of residual biospecimens and clinical data. Participants may withdraw from the study at any time without affecting their subsequent medical care. Biospecimens and clinical data will be assigned unique study identification numbers and managed in a de-identified manner. Personally identifiable information will be stored separately with restricted access. Biospecimens and study data will be stored, managed, and destroyed in accordance with applicable institutional policies and ethical requirements. The study is expected to involve minimal additional risk because it does not require additional blood draws or alter standard clinical care. Treatment response will be evaluated based on the best overall response (BOR) during T+A therapy. The primary efficacy assessment will be performed according to RECIST 1.1, while modified RECIST (mRECIST) will be used as a supportive assessment for HCC-specific response evaluation. Participants will be categorized as responders if their BOR is complete response (CR) or partial response (PR), and as non-responders if their BOR is stable disease (SD) or progressive disease (PD). The primary objective is to compare baseline peripheral blood biomarker levels between responders and non-responders, as defined by RECIST 1.1, and to identify biomarkers associated with treatment benefit. Secondary objectives include evaluating longitudinal biomarker changes from baseline throughout T+A therapy, including fold changes and potential time windows associated with treatment response. Treatment response according to mRECIST will be evaluated as a supportive analysis, and sensitivity analyses based on mRECIST-defined response will be performed to assess the consistency and robustness of biomarker associations and predictive model performance. Predictive models will be developed using least absolute shrinkage and selection operator (LASSO)-based feature selection, with treatment response defined according to RECIST 1.1 as the primary endpoint. Model discrimination will be evaluated using receiver operating characteristic (ROC) curve analysis, including the area under the ROC curve (AUC), sensitivity, and specificity. Predictive performance based on mRECIST-defined response will be explored as a supportive analysis.
Adult patients with histologically or clinically confirmed unresectable or advanced HCC who are scheduled to receive first-line atezolizumab plus bevacizumab therapy at Zhongshan Hospital, Fudan University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention (observational study)
This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Objective Response Rate
Objective response rate, defined as the proportion of participants achieving CR or PR according to RECIST 1.1 based on the BOR during T+A therapy.
Time frame: From treatment initiation up to 12 months.
Baseline Peripheral Blood Biomarker Concentrations
Baseline concentrations of predefined peripheral blood biomarkers measured using ELISAs will be assessed before treatment initiation.
Time frame: Baseline (within 7 days before treatment initiation).
Change From Baseline in Peripheral Blood Biomarker Concentrations
Changes from baseline in concentrations of predefined peripheral blood biomarkers measured using ELISAs will be assessed at serial treatment visits during T+A therapy.
Time frame: Baseline and approximately every 3 weeks during treatment, up to 12 months.
Progression-Free Survival
Progression-free survival (PFS), defined as the time from treatment initiation to the first documented disease progression according to RECIST 1.1 or death from any cause, whichever occurs first.
Time frame: From treatment initiation up to 12 months.
Overall Survival
Overall survival (OS), defined as the time from treatment initiation to death from any cause.
Time frame: From treatment initiation up to 12 months.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 22 months is below that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.